Mycobacterium marinum infection complicated by anti-tumour necrosis factor therapy

Journal of Medical Microbiology

Volumn 59, Issue 5, 2010, Pages 617-621

  Ramos, José M ^a   García Sepulcre, Mariana F ^b   Rodríguez, Juan C ^b   Padilla, Sergio ^a   Gutiérrez, Félix ^a  

^a Infectious Diseases Unit   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CLARITHROMYCIN; CLOXACILLIN; ETHAMBUTOL; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METRONIDAZOLE; OFLOXACIN; PREDNISONE; RIFAMPICIN; RNA 16S; TUMOR NECROSIS FACTOR ANTIBODY; IMMUNOSUPPRESSIVE AGENT; TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ACID FAST BACTERIUM; ADD ON THERAPY; ADULT; ARTICLE; BACTERIAL GROWTH; BACTERIUM CULTURE; BACTERIUM IDENTIFICATION; CASE REPORT; CELLULITIS; CROHN DISEASE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG INFUSION; DRUG SENSITIVITY; DRUG WITHDRAWAL; ERYTHEMA; FOREARM; GENE SEQUENCE; GRANULOMATOUS INFLAMMATION; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; MALE; MICROSCOPY; MYCOBACTERIOSIS; MYCOBACTERIUM MARINUM; MYCOBACTERIUM MARINUM INFECTION; NECROSIS; PAPULE; PHOTOCHROMOGENIC BACTERIUM; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RECTUM DISEASE; SCAR; SIDE EFFECT; SKIN BIOPSY; SKIN DEFECT; SKIN ULCER; SPOROTRICHOSIS; STAINING; SUBCUTANEOUS NODULE; SUPPURATION; THUMB; ATYPICAL MYCOBACTERIOSIS; DRUG ANTAGONISM; ISOLATION AND PURIFICATION; MICROBIOLOGY; PATHOLOGY; SKIN;

ADULT; ANTITUBERCULAR AGENTS; CROHN DISEASE; ETHAMBUTOL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MYCOBACTERIUM INFECTIONS, ATYPICAL; MYCOBACTERIUM MARINUM; RIFAMPIN; SKIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77951646481     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/jmm.0.017277-0     Document Type: Article

References (24)

1. Boulman, N., Rozenbaum, M., Slobodin, G. & Rosner, I. (2006). Mycobacterium fortuitum infection complicating infliximab therapy in rheumatoid arthritis. Clin Exp Rheumatol 24, 723.
2. Chopra, N., Kirschenbaum, A. E. & Widman, D. (2002). Mycobacterium marinum tenosynovitis in a patient on etanercept therapy for rheumatoid arthritis. J Clin Rheumatol 8, 265-268.
3. Danko, J. R., Gilliland, W. R., Miller, R. S. & Decker, C. F. (2009). Disseminated Mycobacterium marinum infection in a patient with rheumatoid arthritis receiving infliximab therapy. Scand J Infect Dis 41, 252-255.
4. Dare, J. A., Jahan, S., Hiatt, K. & Torralba, K. D. (2009). Reintroduction of etanercept during treatment of cutaneous Mycobacterium marinum infection in a patient with ankylosing spondylitis. Arthritis Rheum 61, 583-586.
5. Díaz, F., Urkijo, J. C., Mendoza, F., de la Viuda, J. M., Blanco, M., Unzurrunzaga, A. & Ayarza, R. (2008). Mycobacterium chelonae infection associated with adalimumab therapy. Scand J Rheumatol 37, 159-160.
6. Ehlers, S. (2005). Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept? Clin Infect Dis 41, S199-S203.
7. Fallon, J. C., Patchett, S., Gulmann, C. & Murphy, G. M. (2008). Mycobacterium marinum infection complicating Crohn's disease, treated with infliximab. Clin Exp Dermatol 33, 43-45.
8. Griffith, D. E., Aksamit, T., Brown-Elliott, B. A., Catanzaro, A, Daley, C., Gordin, F., Holland, S. M., Horsburgh, R., Huitt, G. & other authors (2007). An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 175, 367-416.
9. Keane, J., Gershon, S., Wise, R. P., Mirabile-Levens, E., Kasznica, J., Schwieterman, W. D., Siegel, J. N. & Braun, M. M. (2001). Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345, 1098-1104.
10. Malkin, J., Shrimpton, A., Wiselka, M., Barer, M. R., Duddridge, M. & Perera, N. (2009). Olecranon bursitis secondary to Mycobacterium kansasii infection in a patient receiving infliximab for Behcet's disease. J Med Microbiol 58, 371-373.
11. Marie, I., Heliot, P., Roussel, F., Hervé, F., Muir, J. F. & Levesque, H. (2005). Fatal Mycobacterium peregrinum pneumonia in refractory polymyositis treated with infliximab. Rheumatology 44, 1201-1202.
12. Martín-Aspas, A., Guerrero-Sánchez, F., García-Martos, P., González-Moya, E., Medina-Varo, F. & Girón González, J. A. (2008). Bilateral pneumonia by Mycobacterium aurum in a patient receiving infliximab therapy. J Infect 57, 167-169.
13. Mufti, A. H., Toye, B. W., Mckendry, R. R. & Angel, J. B. (2005). Mycobacterium abscessus infection after use of tumor necrosis factor alpha inhibitor therapy: case report and review of infectious complications associated with tumor necrosis factor alpha inhibitor use. Diagn Microbiol Infect Dis 53, 233-238.
14. Pandian, T. K., Deziel, P. J., Otley, C. C., Eid, A. J. & Razonable, R. R. (2008). Mycobacterium marinum infections in transplant recipients: case report and review of the literature. Transpl Infect Dis 10, 358-363.
15. Piersimoni, C. & Scarparo, C. (2009). Extrapulmonary infections associated with nontuberculous mycobacteria in immunocompetent persons. Emerg Infect Dis 15, 1351-1358.
16. Rallis, E., Koumantaki-Mathioudaki, E., Frangoulis, E., Chatziolou, E. & Katsambas, A. (2007). Severe sporotrichoid fish tank granuloma following infliximab therapy. Am J Clin Dermatol 8, 385-388.
17. Salvana, E. M., Cooper, G. S. & Salata, R. A. (2007). Mycobacterium other than tuberculosis (MOTT) infection: an emerging disease in infliximab-treated patients. J Infect 55, 484-487.
18. Shehan, J. M. & Sarma, D. P. (2008). Mycobacterium mucogenicum: report of a skin infection associated with etanercept. Dermatol Online J 14, 5.
19. Streit, M., Böhlen, L. M., Hunziker, T., Zimmerli, S., Tscharner, G. G., Nievergelt, H., Bodmer, T. & Braathen, L. R. (2006). Disseminated Mycobacterium marinum infection with extensive cutaneous eruption and bacteremia in an immunocompromised patient. Eur J Dermatol 16, 79-83.
20. Swart, R. M., van Ingen, J., van Soolingen, D., Slingerland, R., Hendriks, W. D. & den Hollander, J. G. (2009). Nontuberculous mycobacteria infection and tumor necrosis factor-alpha antagonists. Emerg Infect Dis 15, 1700-1701.
21. van Ingen, J., Boeree, M., Janssen, M., Ullmann, E., de Lange, W., de Haas, P., Dekhuijzen, R. & van Soolingen, D. (2007). Pulmonary Mycobacterium szulgai infection and treatment in a patient receiving anti-tumor necrosis factor therapy. Nat Clin Pract Rheumatol 3, 414-419.
22. Wallis, R. S., Broder, M. S., Wong, J. & Beenhouwer, D. (2004). Granulomatous infections due to tumor necrosis factor blockade: correction. Clin Infect Dis 39, 1254-1255.
23. Winthrop, K. L., Chang, E., Yamashita, S., Iademarco, M. F. & LoBue, P. A. (2009). Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapy. Emerg Infect Dis 15, 1556-1561.
24. Yim,K., Nazeer,S.H., Kiska,D.,Rose, F. B.,Brown,D.&Cynamon,M.H. (2004). Recurrent Mycobacterium xenopi infection in a patient with rheumatoid artritis receiving etanercept. Scand J Infect Dis 36, 150-154.